1. Field of the Invention
The present invention relates to the field of accessing a biological lumen and closing the access port thereby created.
2. Description of the Related Art
A number of diagnostic and interventional vascular procedures are now performed translumenally, where a catheter is introduced to the vascular system at a convenient access location—such as the femoral, brachial, or subclavian arteries—and guided through the vascular system to a target location to perform therapy or diagnosis. When vascular access is no longer required, the catheter and other vascular access devices must be removed from the vascular entrance and bleeding at the puncture site must be stopped.
One common approach for providing hemostasis is to apply external force near and upstream from the puncture site, typically by manual compression. This method is time-consuming, frequently requiring one-half hour or more of compression before hemostasis. This procedure is uncomfortable for the patient and frequently requires administering analgesics. Excessive pressure can also present the risk of total occlusion of the blood vessel, resulting in ischemia and/or thrombosis.
After hemostasis is achieved by manual compression, the patient is required to remain recumbent for six to eighteen hours under observation to assure continued hemostasis. During this time bleeding from the vascular access wound can restart, potentially resulting in major complications. These complications may require blood transfusion and/or surgical intervention.
Bioabsorbable fasteners have also been used to stop bleeding. Generally, these approaches rely on the placement of a thrombogenic and bioabsorbable material, such as collagen, at the superficial arterial wall over the puncture site. This method generally presents difficulty locating the interface of the overlying tissue and the adventitial surface of the blood vessel. Implanting the fastener too far from the desired location can result in failure to provide hemostasis. If, however, the fastener intrudes into the vascular lumen, thrombus can form on the fastener. Thrombus can embolize downstream and/or block normal blood flow at the thrombus site. Implanted fasteners can also cause infection and auto-immune reactions/rejections of the implant.
Suturing methods are also used to provide hemostasis after vascular access. The suture-applying device is introduced through the tissue tract with a distal end of the device located at the vascular puncture. Needles in the device draw suture through the blood vessel wall on opposite sides of the punctures, and the suture is secured directly over the adventitial surface of the blood vessel wall to close the vascular access wound.
To be successful, suturing methods need to be performed with a precise control. The needles need to be properly directed through the blood vessel wall so that the suture is well anchored in tissue to provide for tight closure. Suturing methods also require additional steps for the surgeon.
Due to the deficiencies of the above methods and devices, a need exists for a more reliable vascular closure method and device. There also exists a need for a vascular closure device and method that is self-sealing and secure. There also exists a need for a vascular closure device and method requiring no or few extra steps to close the vascular site.
A method for accessing a biological lumen having a lumen wall and surrounding tissue is disclosed. The method includes forming a path between the lumen wall and the surrounding tissue. The method further includes extending the path through the lumen wall. The method also includes opening the path to the lumen.
The method of forming the path can include inserting a device between the lumen wall and the surrounding tissue. Extending the path can include inserting the device through the lumen wall. Opening the path can include inserting the device into the lumen. The method can include delivering a filler into the path.
The method can include filling the path. Filling the path can include delivering a filler into the path. The filler can have a solid-setting liquid. The filler can have an epoxy.
The method can include applying pressure to the path. Applying pressure to the path can include delivering filler adjacent to the path. Delivering filler adjacent to the path can include delivering filler between the lumen wall and the surrounding tissue. Delivering filler can include delivering filler in the lumen wall. Delivering filler can include delivering filler in the surrounding tissue.
Also disclosed is a method for forming an arteriotomy in a lumen having a lumen wall and surrounding tissue. The method includes translating a device substantially between the lumen wall and the surrounding tissue. The method further includes turning the device toward the lumen. The method also includes translating the device through the lumen wall. The method also includes removing the device from the lumen wall.
The surrounding tissue can have adventitia. Turning can include relaxation of a preformed configuration in the device.
The method can also include translating a guide through the device. Translating a guide can include translating the guide into the lumen. The method can also include translating a guide into the lumen. Translating a guide can include translating the guide through the device.
An access device for accessing a biological lumen is disclosed. The device has an introduction device having a relaxed configuration. The relaxed configuration has a first flat section, a first bend at an end of the first flat section, and a first slope extending at a first end from the first bend. The introduction device is configured to be translated with respect to the access device.
The relaxed configuration of the introduction device can have a second bend at a second end of the first slope, a second flat section extending at a first end from the second bend, a third bend at a second end of the second flat section, and a second slope extending from the third bend. The access device can have a delivery guide. The delivery guide can be configured to deliver the introduction device.
The access device can have an anchor. The anchor can extend from the delivery guide. The anchor can be configured to stabilize the access device with respect to the lumen.
A device for accessing a biological lumen is disclosed. The biological lumen has a lumen wall having a longitudinal lumen wall axis. The device has an elongated member that has a longitudinal member axis. The member is configured to access the lumen at a first angle.
U.S. patent application Ser. No. 10/844,247, filed 12 May 2004, is incorporated by reference herein in its entirety. Aspects, characteristics, components or complete embodiments of devices and methods disclosed therein can be used with anything disclosed herein.
The arteriotomy device 2 can have a delivery guide 12. The delivery guide 12 can be slidably attached to an anchor 14. The anchor 14 can be rigid, flexible or combinations thereof. The anchor 14 can be resilient, deformable or combinations thereof. The anchor 14 can be retractable and extendable from the delivery guide 12. The anchor 14 can have a guide eye sheath or an attachable guidewire. The anchor 14 can have an integral, or multiple separate and fixedly attached, wound wire. The anchor 14 can have a wire coating, for example a lubricious coating and/or a coating made from urethane
The anchor 14 can have an anchor longitudinal axis 16. The introduction device can have an introduction longitudinal axis 18. The intersection of the anchor longitudinal axis 16 and the introduction longitudinal axis 18 can be an introduction angle 20. The anchor 14 can be inserted into the biological lumen 4 using a Seldinger technique, modified Seldinger technique, or other method known to one having ordinary skill in the art.
The arteriotomy device 2 can be configured to deliver the introduction device at the introduction angle 20. The introduction device 6 can have an introduction longitudinal axis. The introduction angle 20 can be the intersection of the introduction longitudinal axis 18 and the anchor longitudinal axis 16. The introduction angle 20 can have an absolute value from about 0° to about 30°, more narrowly from about 0° to about 19°, yet more narrowly from about 0° to about 15°, yet more narrowly from about 5° to about 10°, for example about 10°.
Any or all elements of the arteriotomy device 2 or other devices or apparatuses described herein can be made from, for example, a single or multiple stainless steel alloys, nickel titanium alloys (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, Ill.; CONICHROME® from Carpenter Metals Corp., Wyomissing, Pa.), molybdenum alloys (e.g., molybdenum TZM alloy, for example as disclosed in International Pub. No. WO 03/082363 A2, published Oct. 9, 2003, which is herein incorporated by reference in its entirety), tungsten-rhenium alloys, for example, as disclosed in International Pub. No. WO 03/082363, polymers such as polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), carbon fiber composites (e.g., carbon fiber nylon composite, such as carbon fiber reinforced nylon 66), polypropylene, polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ether ketone (PEEK), nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France), aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products, Wilmington, Mass.), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene propylene (FEP), absorbable or resorbable polymers such as polyglycolic acid (PGA), polylactic acid (PLA), polydioxanone, and pseudo-polyamino tyrosine-based acids, extruded collagen, silicone, zinc, echogenic, radioactive, radiopaque materials or combinations thereof. Examples of radiopaque materials are barium sulfate, zinc oxide, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.
Any or all elements of the arteriotomy device 2, including supplemental closure devices, such as filler, or other devices or apparatuses described herein can be or have a matrix for cell ingrowth or used with a fabric, for example a covering (not shown) that acts as a matrix for cell ingrowth. The matrix and/or fabric can be, for example, polyester (e.g., DACRON® from E. I. du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE, ePTFE, nylon, extruded collagen, silicone or combinations thereof.
The elements of the arteriotomy device 2 and/or the filler and/or the fabric can be filled and/or coated with an agent delivery matrix known to one having ordinary skill in the art and/or a therapeutic and/or diagnostic agent. The agents within these matrices can include radioactive materials; radiopaque materials; cytogenic agents; cytotoxic agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-inflammatories (NSAIDs) such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, Pa.; indomethacin; niefenamic acid), COX-2 inhibitors (e.g., VIOXX® from Merck & Co., Inc., Whitehouse Station, N.J.; CELEBREX® from Pharmacia Corp., Peapack, N.J.; COX-1 inhibitors); immunosuppressive agents, for example Sirolimus (RAPAMUNE®, from Wyeth, Collegeville, Pa.), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms, Circulation, Jul. 6, 1999, 48-54; Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae, Brit. J Surgery 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit. J Surgery 86 (6), 771-775; Xu et al, Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, J. Biological Chemistry 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms, J. Clinical Investigation 105 (11), 1641-1649 which are all incorporated by reference in their entireties.
The delivery guide 12 can be deployed through the surrounding tissue 10 and into the lumen wall 8 and/or the lumen 4. As illustrated in FIGS. 45 and 46 of U.S. patent application Ser. No. 10/844,247 for a toggle deployment device, the arteriotomy device 2 can have a pressure check port. The pressure check port can be in fluid communication with a sensor or port on or near the handle of the arteriotomy device 2, such as an external lumen where blood flow can be observed, for example from flow from the end of an external tube or port and/or through a transparent or translucent window. The pressure check port can facilitate deployment of the arteriotomy device 2 to a location where the pressure check port is introduced to pressure, for example when the pressure check port enters the biological lumen 4. The sensor or port on or near the handle of the arteriotomy device 2 will signal that the pressure check port has been placed into the biological lumen 4 (e.g., by displaying a small amount of blood flow). The pressure check port can be deployed into the biological lumen 4 and then withdrawn from the biological lumen 4 to the point where the lumen wall 8 just stops the pressure in the pressure check port. An entry wall retainer port can additionally perform the function as described herein for the pressure check port.
The delivery guide 12 can form a first arteriotomy 22. When the anchor 14 is properly located in the lumen 4, a luminal retainer 24 and/or an entry wall retainer 26 can be deployed from the anchor 14 and/or the delivery guide 12. The anchor 14, and/or luminal retainer 24, and/or entry wall retainer 26 can be wires, rods, inflatable balloons, or combinations thereof. The anchor 14, and/or luminal retainer 24, and/or entry wall retainer 26 can be separate, integral or a single component.
When the anchor 14 is properly located in the lumen 4, the introduction device 6 can be translated, as shown by arrow. The introduction device can form a second arteriotomy 28. The introduction device 6 can create a cleavage 30 between the lumen wall 8 and the surrounding tissue 10. The introduction device 6 can cleave a plane in the lumen wall 8, as shown in
Once the lumen wall 8, and/or the surrounding tissue 10, and/or the cleavage 30 has been cleaved, a subintimal angioplasty can be performed as known to one having ordinary skill in the art. Once the lumen wall 8, and/or the surrounding tissue 10, and/or the cleavage 30 has been cleaved, a remote endarterectomy can be performed as known to one having ordinary skill in the art.
The introduction device 6 can have one or more straights and/or bends. Various bent introduction devices 34 and straight introduction devices 36 can be swapped during use to selectively cleave the lumen wall 8 and/or the surrounding tissue 10 and/or the cleavage 30. Tools, such as guides (e.g., guidewires), can be inserted through hollow introduction devices 6 to selectively cleave.
As shown in
The introduction device 6 can pass through an introduction run 38 and an introduction rise 40. The introduction run 38 can be the component of the length of the introduction device 6 in the lumen wall 8 that is parallel to the lumen wall 8. The introduction run 38 can be the component of the length parallel to the lumen wall 8 between the opening of the second arteriotomy 28 on the outside of the lumen wall 8 and the opening of the second arteriotomy 28 on the inside lumen wall surface 32. The introduction run 38 can be from about 0.10 cm (0.010 in.) to about 3.810 cm (1.500 in.), for example about 0.64 cm (0.25 in.).
The introduction rise 40 can be the component of the length of the introduction device 6 in the lumen wall 8 that is perpendicular to the lumen wall 8. The introduction rise 40 can be the component of the length perpendicular to the lumen wall 8 between the opening of the second arteriotomy 28 on the outside of the lumen wall 8 and the opening of the second arteriotomy 28 on the inside lumen wall surface 32. The introduction rise 40 can be from about 0.51 mm (0.020 in.) to about 5.08 mm (0.200 in.), for example about 1.0 mm (0.040 in.).
An introduction slope can be the ratio of the introduction rise 40 to the introduction run 38. The introduction slope can be from about ½ to about 1/40 or less, for example about ⅙, also for example about ⅓. The introduction slope can be, for examples, equal to or less than about ½ or ⅓, more narrowly equal to or less than about ⅓ or ¼, yet more narrowly equal to or less than about ⅕ or ⅙, even still more narrowly than about equal to or less than about 1/10.
The introduction rise 40 and the introduction run 38 can be components of an introduction vector. The introduction run 38 can be the component of the introduction vector parallel to the lumen wall 8. The introduction rise 40 can be the component of the introduction vector perpendicular to the lumen wall 8. The introduction vector can be a vector from an outer opening 42 to an inner opening 44. The outer opening 42 can be a temporary or permanent opening in the lumen wall 8 or in the surrounding tissue 10 formed by the initial translation of the introduction device 6 out of the delivery guide 12. The inner opening 44 can be a temporary or permanent opening on the lumen wall surface 32.
An introducer sheath (not shown) can be inserted over the guidewire 46 and/or over or through the introduction device 6. The introducer sheath can be less than about 22 French (7.3 mm, 0.29 in. diameter) or less than the diameter of the lumen to which the introducer sheath is introduced. The introducer sheath can be, for examples, about 6 French (2.3 mm, 0.092 in. diameter), and about 8 French (2.67 mm, 0.105 in. diameter). The introducer sheath can be known to one having ordinary skill in the art, for example the introducer sheath described in U.S. Pat. No. 5,183,464 to Dubrul, et al.
The introducer sheath can be inserted into the second arteriotomy 28. The introducer sheath can expand the second arteriotomy 28 to a desired or workable size. The introducer sheath can be inserted into the second arteriotomy 28 before and/or after and/or concurrently with when the filler, described infra, is deployed and/or other closure methods or devices are used.
The second arteriotomy 28 can have an arteriotomy cross-section that can have an arteriotomy diameter 54. The arteriotomy diameter 54 can be from about 0.5 mm (0.020 in.) to about 400 mm (15 in.), yet a narrower range from about 1.0 mm (0.040 in.) to about 10.2 mm (0.400 in.), for example about 2.54 mm (0.100 in.). The arteriotomy diameter 54 can be about the diameter of the introduction device 6.
The arteriotomy cross-section can be non-circular. The arteriotomy can have an arteriotomy width and an arteriotomy height. The arteriotomy width can be about half the circumference of the arteriotomy. The arteriotomy width can be from about 1.0 mm (0.040 in.) to about 10.2 mm (0.400 in.), for example about 4.06 mm (0.160 in.).
The arteriotomy height 152 can be less than about 0.51 mm (0.020 in.), more narrowly, less than about 0.38 mm (0.015 in.). The arteriotomy height can be from about 0.25 mm (0.010 in.) to about 1.3 mm (0.050 in.), for example about 0.38 mm (0.015 in.). The arteriotomy diameter, and/or height, and/or width can be small enough to enable cell growth, blood clotting, acoustic sealing, heat sealing, gluing, enhanced self-sealing and combinations thereof across the second arteriotomy 28.
The delivery guide 12 and/or other components of the arteriotomy device 2 can form a delivery path 56 during use. During percutaneous use, the delivery path can extend to the skin 138.
The second arteriotomy 28 can have a flat 58 and a slope 60. The flat 58 can be the cleavage 30 between the lumen wall 8 and the surrounding tissue.
The filler 70 can be delivered (e.g., injected and/or implanted) into the second arteriotomy 28 through the surrounding tissue 10, for example by percutaneous injection. The filler 70 can be delivered (e.g., injected and/or implanted) into the second arteriotomy 28 through the second arteriotomy 28, for example via the introduction device 6 during introduction and/or removal of the introduction device 6.
The filler 70 can be permanently or temporarily deployed. The filler 70 can biodissolve after hemostasis is achieved and/or after the arteriotomy is substantially or completely healed. The filler 70 can be maintained from about 15 minutes to about 24 hours or more, for example about 120 minutes.
The filler 70 can be between the second arteriotomy 28 and the lumen 4 (not shown). The filler 70 can be in the surrounding tissue 10.
The anchor 14 can have an anchor first length 78 extending from the delivery guide 12. The anchor 14 can have an anchor first bend 80 at the end of the first anchor length 78 distal to the delivery guide 12. An anchor second length 82 can extend at a first end from the anchor first bend 80. A second end of the anchor second length 82 can have an anchor second bend 84. An anchor third length 86 can extend from the anchor second bend 84. The anchor third length 86 can terminate. The anchor 14 can have any combination of lengths and bends.
The radius of curvature for the anchor bends 80 and 84 can be from about 0.1 mm (0.004 in.) to about 2.0 mm (0.079 in.). The anchor lengths on both sides of any anchor bend can form an anchoring angle. The anchoring angles can be from about 90° to about 160°, more narrowly from about 120° to about 150°, for example about 135°. The anchor 14 can have a cross-section having an anchor diameter from about 0.38 mm (0.015 in.) to about 1.0 mm (0.039 in.), for example about 0.71 mm (0.028 in.).
The anchor third length 86 can have an anchor tip 88. The anchor tip 88 can be narrowed, widened, sharpened, dulled, or otherwise configured to promote sharp or blunt dissection. The anchor tip 88 can have an anchor end port 90. The anchor end port 90 can be in communication with an anchor guidewire lumen (not shown). The anchor guidewire lumen can be in communication with a guide lumen 92 in the delivery guide extension 76, and/or the handle 74, and/or a third control 94. The guide lumen 92 can have open access along the delivery guide extension 76, and/or along the handle 74, and/or along the third control 94 (as shown).
The handle 74 can have a first control 96. The first control 96 can be slidably attached to a control slide 98. The first control 96 can be configured to be ergonomically receptive to be activated a digit and/or a palm.
The handle 74 can have a second control 100. The second control 100 can be rotatably attached to the handle 74, for example at a control pivot 102. The second control 100 can have a tab 104. The tab 104 can be configured to be ergonomically receptive to be activated by a digit and/or a palm.
The handle 74 can have a third control 94. The third control can be slidably attached to the handle 74. The third control 94 can have or be a plunger. The third control 94 can have a press 106. The press 106 can be configured to be ergonomically receptive to be activated by a digit and/or a palm. The handle 74 can have one or more grips 108. The grips 108 can be configured to be ergonomically receptive to be held by a digit and/or a palm.
The configuration of any of the first, second or third controls 96, 100 and 94 can be any configuration (e.g., the first control can have the rotatable lever of the second control 100).
A guidewire 46 can be in proximity to the anchor tip 88.
The guidewire 46 can be used to deploy the arteriotomy device to a desired location in a lumen. The arteriotomy device 2 can be translated, for example percutaneously, over and along the guidewire 46. If the guidewire 46 is in a lumen, the arteriotomy device 2 can be translated along the guidewire 46, for example, until blood appears at the pressure check port.
The luminal retainer 24 can be a wire, scaffold or stent—for example made from a deformable or resilient material, such as a shape memory alloy—an inflatable balloon, or combinations thereof. Intralumenal inflatable balloons, such as those inflated with saline solution or carbon dioxide, are known to those having ordinary skill in the art. The luminal retainer 24 can extend into the delivery guide 12.
The luminal retainer 24 can be configured to press against the lumen 4 during use. The luminal retainer can be deployed by translating, rotating or a combination thereof, with respect to the anchor 14.
The luminal retainer 24 can deploy from the anchor 14. The luminal retainer 24 can deploy from a luminal retainer port (not shown). The luminal retainer 24 can have a luminal retainer deployed diameter. The luminal retainer deployed diameter can be from about 2.54 mm (0.100 in.) to about 10.2 mm (0.400 in.), for example about 6.35 mm (0.250 in.).
The anchor first length 78 can have an anchor shift 110 or small inflection. The anchor shift 110 can be configured wherein the anchor first length 78 shifts perpendicular to the longitudinal axis of the delivery guide 12, as seen in
When the anchor is retracted into the delivery guide 12, an introduction lumen exit port 112 can be exposed. When the anchor is retracted into the delivery guide 12, the anchor shift 110, laterally positioned compared to the rest of the anchor first length 78, can expose the introduction lumen exit port 112. When the anchor is retracted into the delivery guide 12, the anchor shift 110, laterally positioned compared to the rest of the anchor first length 78, can force the entire anchor 14 to move laterally, thereby exposing the introduction lumen exit port 112.
The introduction device 6 can have an introduction device diameter. The introduction device diameter can be from about 0.25 mm (0.010 in.) to about 1.0 mm (0.039 in.), for example about 0.56 mm (0.022 in.).
The arteriotomy device 2 can be configured to deploy the introduction device 6 from the anchor 14 and/or the delivery guide 12 (as shown). The anchor 14 and/or delivery guide 12 can have the introduction lumen exit port 112. The introduction device 6 can deploy through the introduction lumen exit port 112. The introduction device 6 can be a solid or hollow needle, or combinations thereof.
The radiopaque marks can be marks for any type of medical imagining. For example, the marks could be sono-opaque and/or sono-reflective for use with sonographs.
The introduction device 6 can have a bend 34. The bend 34 can be in a relaxed configuration of the introduction device 6. If the introduction device 6 is deployed far enough, the bend 34 can rotate the introduction device 6 toward the lumen 4.
The first, second and third controls 96, 100 and 94 can have lockouts to prevent the controls 96, 100 and 94 from being activated incorrectly (e.g., to prevent use in the wrong order).
An extension attachment 144 can be configured to fixedly attach to the delivery guide extension 76. The extension abutment 146 can be configured to abut against and/or fixedly attach to the delivery guide extension 76. The extension attachment 144 and/or extension abutment 146 can form fluid-tight and/or air-tight seals with the delivery guide extension 76.
The anchor lumen 148 can be configured to receive and deploy the anchor 14 out the anchor exit port 150. The introducer lumen 152 can be configured to receive and deploy the introduction device 6 out the introduction lumen exit port 112. The relative geometries of the anchor lumen 148, the introducer lumen 152, the anchor exit port 150, and the introduction lumen exit port 112 can be changed to alter the introduction angle 20, introduction run 38, introduction rise 40, and the geometry of the arteriotomy 134 including the geometries of the slopes 60 and flats 58 of the arteriotomy 134.
The delivery guide half attachments 154 can attach the first longitudinal section 140 to the second longitudinal section 142, for example by rotatably attaching to a screw. The seam surfaces 156 of the first longitudinal section 140 can form fluid-tight and/or air-tight seals with the seam surfaces 156 of the second longitudinal section 142. The delivery guide tip 158 can be sharpened, dulled, or otherwise configured to aid sharp or blunt dissection.
As shown in
As shown in
Any of the introduction devices 6 shown in
The guides 172 and/or guide lumens 92 and/or introduction devices 6 can have a lubricious coating or be impregnated to elute a lubricious material.
The introduction device 6, for example a hollow introduction device 6, can act as a pathway for a luminal tool, for example tools such as a guidewire 46, to be deployed into the lumen 4. The introduction device 6, for example a solid introduction device 6, can be removed from the second arteriotomy 28 and the luminal tool can be deployed through, for example, the introduction lumen exit port 112, and the second arteriotomy 28. The introduction device 6, or part thereof, can be the luminal tool, for example the guide 172. The introduction device 6 can be further deployed and used as a luminal tool after passing through the lumen wall 8.
The guide 172 can remain substantially in place after the arteriotomy device 2 is removed. A portion of the guide 172 can be outside the lumen 4 and another portion of the guide 172 can be inside the lumen 4. The guide proximal end can then be attached to additional devices and implants to guide the devices and implants into the lumen. The filler 70 can be added after additional procedures are completed and the guide 172 is removed, or before the guide 172 is removed, using the guide 172 to redeploy the arteriotomy device 2 back to the arteriotomy 134 to deliver the filler 70.
Method of Manufacture
The elements of the arteriotomy device 2, and those of any other devices and components disclosed herein, can be directly attached by, for example, melting, screwing, gluing, welding or use of an interference fit or pressure fit such as crimping, snapping, or combining methods thereof. The elements can be integrated, for example, molding, die cutting, laser cutting, electrical discharge machining (EDM) or stamping from a single piece or material. Any other methods can be used as known to those having ordinary skill in the art.
Integrated parts can be made from pre-formed resilient materials, for example resilient alloys (e.g., Nitinol, ELGILOY®) that are preformed and biased into the post-deployment shape and then compressed into the deployment shape as known to those having ordinary skill in the art.
Any elements of the arteriotomy device 2, and those of any other devices and components disclosed herein, including the supplemental closure devices, as a whole after assembly, can be coated by dip-coating, brush-coating or spray-coating methods known to one having ordinary skill in the art.
One example of a method used to coat a medical device for vascular use is provided in U.S. Pat. No. 6,358,556 by Ding et al. and hereby incorporated by reference in its entirety. Time release coating methods known to one having ordinary skill in the art can also be used to delay the release of an agent in the coating, for example the coatings on the supplemental closure devices.
Any elements herein can be covered with a fabric, for example polyester (e.g., DACRON® from E. I. du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE, ePTFE, nylon, extruded collagen, silicone or combinations thereof. Methods of covering an implantable device with fabric are known to those having ordinary skill in the art.
As shown in
The radiopaque marks can be attached to the elements and/or coated on the surface of the elements and/or manufactured integrally in the elements.
The introduction device 6, guide 172, anchor 14, luminal retainer 24, entry wall retainer 26, any other elements, or combinations thereof can be heat set in a relaxed configuration using methods know to those having ordinary skill in the art.
It is apparent to one skilled in the art that various changes and modifications can be made to this disclosure, and equivalents employed, without departing from the spirit and scope of the invention. Elements shown with any embodiment are exemplary for the specific embodiment and can be used on other embodiments within this disclosure.
This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application 60/680,388 filed May 12, 2005, the content of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2857925 | Higginbotham | Jun 1955 | A |
3727614 | Kniazuk | Apr 1973 | A |
3730185 | Cook et al. | May 1973 | A |
4006747 | Kronenthal et al. | Feb 1977 | A |
4744364 | Kensey | May 1988 | A |
4774949 | Fogarty | Oct 1988 | A |
4850960 | Grayzel | Jul 1989 | A |
4890611 | Monfort et al. | Jan 1990 | A |
4921484 | Hillstead | May 1990 | A |
4955897 | Ship | Sep 1990 | A |
4962755 | King et al. | Oct 1990 | A |
5183464 | Dubrul et al. | Feb 1993 | A |
5271415 | Foerster et al. | Dec 1993 | A |
5304184 | Hathaway et al. | Apr 1994 | A |
5336221 | Anderson | Aug 1994 | A |
5358507 | Daily | Oct 1994 | A |
5364359 | van den Haak | Nov 1994 | A |
5364389 | Anderson | Nov 1994 | A |
5368601 | Sauer et al. | Nov 1994 | A |
5380290 | Makower et al. | Jan 1995 | A |
5383897 | Wholey | Jan 1995 | A |
5391182 | Chin | Feb 1995 | A |
5391183 | Janzen et al. | Feb 1995 | A |
5403329 | Hinchcliffe | Apr 1995 | A |
5415657 | Taymor-Luria | May 1995 | A |
5417699 | Klein et al. | May 1995 | A |
5437665 | Munro | Aug 1995 | A |
5439469 | Heaven et al. | Aug 1995 | A |
5451230 | Steinert | Sep 1995 | A |
5462561 | Voda | Oct 1995 | A |
5467786 | Allen et al. | Nov 1995 | A |
5470338 | Whitfield et al. | Nov 1995 | A |
5474568 | Scott | Dec 1995 | A |
5476470 | Fitzgibbons, Jr. | Dec 1995 | A |
5489288 | Buelna | Feb 1996 | A |
5496332 | Sierra et al. | Mar 1996 | A |
5496334 | Klundt et al. | Mar 1996 | A |
5503634 | Christy | Apr 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5527321 | Hinchliffe | Jun 1996 | A |
5527322 | Klein et al. | Jun 1996 | A |
5536255 | Moss | Jul 1996 | A |
5571169 | Plaia et al. | Nov 1996 | A |
5613974 | Andreas et al. | Mar 1997 | A |
5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
5622188 | Plaia et al. | Apr 1997 | A |
5645566 | Brenneman et al. | Jul 1997 | A |
5653717 | Ko et al. | Aug 1997 | A |
5695504 | Gifford, III et al. | Dec 1997 | A |
5700273 | Buelna et al. | Dec 1997 | A |
5709224 | Behl et al. | Jan 1998 | A |
5746755 | Wood et al. | May 1998 | A |
5762066 | Law et al. | Jun 1998 | A |
5766183 | Sauer | Jun 1998 | A |
5772673 | Cuny et al. | Jun 1998 | A |
5779719 | Klein et al. | Jul 1998 | A |
5792152 | Klein et al. | Aug 1998 | A |
5797929 | Andreas et al. | Aug 1998 | A |
5810810 | Tay et al. | Sep 1998 | A |
5817108 | Poncet | Oct 1998 | A |
5830232 | Hasson | Nov 1998 | A |
5836955 | Buelna et al. | Nov 1998 | A |
5846253 | Buelna et al. | Dec 1998 | A |
5860990 | Nobles et al. | Jan 1999 | A |
5860991 | Klein et al. | Jan 1999 | A |
5868762 | Cragg et al. | Feb 1999 | A |
5882302 | Driscoll, Jr. et al. | Mar 1999 | A |
5902311 | Andreas et al. | May 1999 | A |
5921994 | Andreas et al. | Jul 1999 | A |
5941897 | Myers | Aug 1999 | A |
5954732 | Hart et al. | Sep 1999 | A |
5972005 | Stalker et al. | Oct 1999 | A |
5972013 | Schmidt | Oct 1999 | A |
5980539 | Kontos | Nov 1999 | A |
5984917 | Fleischman et al. | Nov 1999 | A |
5984948 | Hasson | Nov 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
6033401 | Edwards et al. | Mar 2000 | A |
6036699 | Andreas et al. | Mar 2000 | A |
6036721 | Harren et al. | Mar 2000 | A |
6042601 | Smith | Mar 2000 | A |
6063085 | Tay et al. | May 2000 | A |
6071292 | Makower et al. | Jun 2000 | A |
6071300 | Brenneman et al. | Jun 2000 | A |
6077276 | Kontos | Jun 2000 | A |
6080175 | Hogendijk | Jun 2000 | A |
6093173 | Balceta et al. | Jul 2000 | A |
6117144 | Nobles et al. | Sep 2000 | A |
6117145 | Wood et al. | Sep 2000 | A |
6136010 | Modesitt et al. | Oct 2000 | A |
6139560 | Kremer | Oct 2000 | A |
6143004 | Davis et al. | Nov 2000 | A |
6146397 | Harkrider, Jr. | Nov 2000 | A |
6152918 | Padilla et al. | Nov 2000 | A |
6159232 | Nowakowski | Dec 2000 | A |
6171317 | Jackson et al. | Jan 2001 | B1 |
6179832 | Jones et al. | Jan 2001 | B1 |
6190396 | Whitin et al. | Feb 2001 | B1 |
6197042 | Ginn et al. | Mar 2001 | B1 |
6203554 | Roberts | Mar 2001 | B1 |
6206893 | Klein et al. | Mar 2001 | B1 |
6206895 | Levinson | Mar 2001 | B1 |
6245079 | Nobles et al. | Jun 2001 | B1 |
6258084 | Goldman et al. | Jul 2001 | B1 |
6302898 | Edwards et al. | Oct 2001 | B1 |
6358244 | Newman et al. | Mar 2002 | B1 |
6358556 | Ding et al. | Mar 2002 | B1 |
6371975 | Cruise et al. | Apr 2002 | B2 |
6383208 | Sancoff et al. | May 2002 | B1 |
6395015 | Borst et al. | May 2002 | B1 |
6398782 | Pecor et al. | Jun 2002 | B1 |
6454777 | Green | Sep 2002 | B1 |
6457182 | Szczesuil et al. | Oct 2002 | B1 |
6458147 | Cruise et al. | Oct 2002 | B1 |
6468228 | Topel et al. | Oct 2002 | B1 |
6475182 | Hnojewyj et al. | Nov 2002 | B1 |
6506210 | Kanner | Jan 2003 | B1 |
6517553 | Klein et al. | Feb 2003 | B2 |
6524321 | Kanesaka | Feb 2003 | B2 |
6524326 | Zhu et al. | Feb 2003 | B1 |
6533795 | Tran et al. | Mar 2003 | B1 |
6562059 | Edwards et al. | May 2003 | B2 |
6565583 | Deaton et al. | May 2003 | B1 |
6569012 | Lydon et al. | May 2003 | B2 |
6623510 | Carley et al. | Sep 2003 | B2 |
6626855 | Weng et al. | Sep 2003 | B1 |
6641592 | Sauer et al. | Nov 2003 | B1 |
6656136 | Weng et al. | Dec 2003 | B1 |
6663655 | Ginn et al. | Dec 2003 | B2 |
6676685 | Pedros et al. | Jan 2004 | B2 |
6682489 | Tenerz et al. | Jan 2004 | B2 |
6689152 | Balceta et al. | Feb 2004 | B2 |
6719694 | Weng et al. | Apr 2004 | B2 |
6719750 | Varner et al. | Apr 2004 | B2 |
6733515 | Edwards et al. | May 2004 | B1 |
6743195 | Zucker | Jun 2004 | B2 |
6749621 | Pantages et al. | Jun 2004 | B2 |
6749622 | McGuckin, Jr. et al. | Jun 2004 | B2 |
6767356 | Kanner et al. | Jul 2004 | B2 |
6773699 | Soltz et al. | Aug 2004 | B1 |
6780197 | Roe et al. | Aug 2004 | B2 |
6790220 | Morris et al. | Sep 2004 | B2 |
6802822 | Dodge | Oct 2004 | B1 |
6818008 | Cates et al. | Nov 2004 | B1 |
6840952 | Saker et al. | Jan 2005 | B2 |
6843792 | Nishtala et al. | Jan 2005 | B2 |
6846319 | Ginn et al. | Jan 2005 | B2 |
6846320 | Ashby et al. | Jan 2005 | B2 |
6846321 | Zucker | Jan 2005 | B2 |
6860895 | Akerfeldt et al. | Mar 2005 | B1 |
6863680 | Ashby | Mar 2005 | B2 |
6890342 | Zhu et al. | May 2005 | B2 |
6890343 | Ginn et al. | May 2005 | B2 |
6890344 | Levinson | May 2005 | B2 |
6893431 | Naimark et al. | May 2005 | B2 |
6896692 | Ginn et al. | May 2005 | B2 |
6918890 | Schmidt | Jul 2005 | B2 |
6929655 | Egnelöv et al. | Aug 2005 | B2 |
6936053 | Weiss | Aug 2005 | B1 |
6939348 | Malecki et al. | Sep 2005 | B2 |
6939357 | Navarro et al. | Sep 2005 | B2 |
6939363 | Akerfeldt | Sep 2005 | B2 |
6939364 | Soltz et al. | Sep 2005 | B1 |
6942674 | Belef et al. | Sep 2005 | B2 |
6949080 | Wolf et al. | Sep 2005 | B2 |
6949107 | McGuckin, Jr. et al. | Sep 2005 | B2 |
6949114 | Milo et al. | Sep 2005 | B2 |
6964668 | Modesitt et al. | Nov 2005 | B2 |
6969397 | Ginn | Nov 2005 | B2 |
6981983 | Rosenblatt et al. | Jan 2006 | B1 |
6994686 | Cruise et al. | Feb 2006 | B2 |
7001400 | Modesitt et al. | Feb 2006 | B1 |
7008440 | Sing et al. | Mar 2006 | B2 |
7008442 | Brightbill | Mar 2006 | B2 |
7025746 | Tal | Apr 2006 | B2 |
7025776 | Houser et al. | Apr 2006 | B1 |
7029489 | Ashby et al. | Apr 2006 | B1 |
7037322 | Sing et al. | May 2006 | B1 |
7037323 | Sing et al. | May 2006 | B2 |
7041119 | Green | May 2006 | B2 |
7074232 | Kanner et al. | Jul 2006 | B2 |
7077848 | de Juan, Jr. et al. | Jul 2006 | B1 |
7081125 | Edwards et al. | Jul 2006 | B2 |
7083628 | Bachmen | Aug 2006 | B2 |
7141055 | Abrams et al. | Nov 2006 | B2 |
7175646 | Brenneman | Feb 2007 | B2 |
7179270 | Makower | Feb 2007 | B2 |
7182763 | Nardella | Feb 2007 | B2 |
7186251 | Malecki et al. | Mar 2007 | B2 |
7226467 | Lucatero et al. | Jun 2007 | B2 |
7235087 | Modesitt et al. | Jun 2007 | B2 |
7247162 | Thornton | Jul 2007 | B1 |
7250028 | Julian et al. | Jul 2007 | B2 |
7279001 | Addis et al. | Oct 2007 | B2 |
7291159 | Schmelzeisen-Redeker et al. | Nov 2007 | B2 |
7316704 | Bagaoisan et al. | Jan 2008 | B2 |
7322976 | Yassinzadeh | Jan 2008 | B2 |
7335220 | Khosravi et al. | Feb 2008 | B2 |
7361180 | Saadat et al. | Apr 2008 | B2 |
7361183 | Ginn | Apr 2008 | B2 |
7377927 | Burdulis et al. | May 2008 | B2 |
7381210 | Zarbatany et al. | Jun 2008 | B2 |
7390328 | Modesitt | Jun 2008 | B2 |
7390329 | Westra et al. | Jun 2008 | B2 |
7470237 | Beckman et al. | Dec 2008 | B2 |
7494460 | Haarstad et al. | Feb 2009 | B2 |
7572274 | Yassinzadeh | Aug 2009 | B2 |
7597705 | Forsberg et al. | Oct 2009 | B2 |
7609673 | Bergenlid et al. | Oct 2009 | B2 |
7621925 | Saadat et al. | Nov 2009 | B2 |
7621936 | Cragg et al. | Nov 2009 | B2 |
7635329 | Goldfarb et al. | Dec 2009 | B2 |
7662128 | Salcudean et al. | Feb 2010 | B2 |
7678133 | Modesitt | Mar 2010 | B2 |
7704261 | Sakamoto et al. | Apr 2010 | B2 |
7704264 | Ewers et al. | Apr 2010 | B2 |
7736347 | Kaplan et al. | Jun 2010 | B2 |
7762977 | Porter et al. | Jul 2010 | B2 |
7837696 | Modesitt et al. | Nov 2010 | B2 |
7842047 | Modesitt et al. | Nov 2010 | B2 |
7846170 | Modesitt et al. | Dec 2010 | B2 |
7850654 | Belhe et al. | Dec 2010 | B2 |
7850701 | Modesitt et al. | Dec 2010 | B2 |
7867249 | Palermo et al. | Jan 2011 | B2 |
7875052 | Kawaura et al. | Jan 2011 | B2 |
20010031922 | Weng et al. | Oct 2001 | A1 |
20010047165 | Makower et al. | Nov 2001 | A1 |
20020016614 | Klein et al. | Feb 2002 | A1 |
20020062146 | Makower et al. | May 2002 | A1 |
20020156495 | Brenneman et al. | Oct 2002 | A1 |
20030093093 | Modesitt et al. | May 2003 | A1 |
20030100921 | Addis et al. | May 2003 | A1 |
20030158578 | Pantages et al. | Aug 2003 | A1 |
20030233120 | Akerfeldt | Dec 2003 | A1 |
20030236542 | Makower | Dec 2003 | A1 |
20040044350 | Martin et al. | Mar 2004 | A1 |
20040086951 | Archakov et al. | May 2004 | A1 |
20040092964 | Modesitt et al. | May 2004 | A1 |
20040093024 | Lousararian et al. | May 2004 | A1 |
20040097978 | Modesitt et al. | May 2004 | A1 |
20040122449 | Modesitt et al. | Jun 2004 | A1 |
20040138522 | Haarstad et al. | Jul 2004 | A1 |
20040143290 | Brightbill | Jul 2004 | A1 |
20040153123 | Palermo et al. | Aug 2004 | A1 |
20040158287 | Cragg et al. | Aug 2004 | A1 |
20040172058 | Edwards et al. | Sep 2004 | A1 |
20040176758 | Yassinzadeh et al. | Sep 2004 | A1 |
20040215232 | Belhe et al. | Oct 2004 | A1 |
20040220594 | de Canniere | Nov 2004 | A1 |
20040220604 | Fogarty et al. | Nov 2004 | A1 |
20040267307 | Bagaoisan et al. | Dec 2004 | A1 |
20040267308 | Bagaoisan et al. | Dec 2004 | A1 |
20050033361 | Galdonik et al. | Feb 2005 | A1 |
20050049634 | Chopra | Mar 2005 | A1 |
20050075653 | Saadat et al. | Apr 2005 | A1 |
20050085773 | Forsberg | Apr 2005 | A1 |
20050085851 | Fiehler et al. | Apr 2005 | A1 |
20050085852 | Ditter | Apr 2005 | A1 |
20050085854 | Ginn | Apr 2005 | A1 |
20050085855 | Forsberg | Apr 2005 | A1 |
20050085856 | Ginn | Apr 2005 | A1 |
20050090860 | Paprocki | Apr 2005 | A1 |
20050096697 | Forsberg et al. | May 2005 | A1 |
20050107826 | Zhu et al. | May 2005 | A1 |
20050125030 | Forsberg et al. | Jun 2005 | A1 |
20050143761 | Modesitt et al. | Jun 2005 | A1 |
20050149065 | Modesitt | Jul 2005 | A1 |
20050228443 | Yassinzadeh | Oct 2005 | A1 |
20050234507 | Geske et al. | Oct 2005 | A1 |
20050251189 | Saadat et al. | Nov 2005 | A1 |
20050267520 | Modesitt | Dec 2005 | A1 |
20050267522 | Yassinzadeh et al. | Dec 2005 | A1 |
20050277980 | Yassinzadeh | Dec 2005 | A1 |
20060009802 | Modesitt | Jan 2006 | A1 |
20060064159 | Porter et al. | Mar 2006 | A1 |
20060079914 | Modesitt et al. | Apr 2006 | A1 |
20060111741 | Nardella | May 2006 | A1 |
20060129101 | McGuckin, Jr. | Jun 2006 | A1 |
20060135990 | Johnson | Jun 2006 | A1 |
20060135991 | Kawaura et al. | Jun 2006 | A1 |
20060136035 | Hermann et al. | Jun 2006 | A1 |
20060142785 | Modesitt et al. | Jun 2006 | A1 |
20060167476 | Burdulis, Jr. et al. | Jul 2006 | A1 |
20060206125 | Fogarty et al. | Sep 2006 | A1 |
20060235449 | Schubart et al. | Oct 2006 | A1 |
20060259017 | Heil, Jr. | Nov 2006 | A1 |
20060264975 | Pipenhagen et al. | Nov 2006 | A1 |
20060271078 | Modesitt | Nov 2006 | A1 |
20070027454 | Modesitt | Feb 2007 | A1 |
20070027455 | Modesitt | Feb 2007 | A1 |
20070032802 | Modesitt | Feb 2007 | A1 |
20070032803 | Modesitt | Feb 2007 | A1 |
20070032804 | Modesitt | Feb 2007 | A1 |
20070106246 | Modesitt | May 2007 | A1 |
20070167959 | Modesitt et al. | Jul 2007 | A1 |
20070255313 | Modesitt | Nov 2007 | A1 |
20080097347 | Arvanaghi | Apr 2008 | A1 |
20090105744 | Modesitt et al. | Apr 2009 | A1 |
20090318889 | Modesitt | Dec 2009 | A1 |
20100016786 | Drews et al. | Jan 2010 | A1 |
20100016810 | Drews et al. | Jan 2010 | A1 |
20100125296 | Modesitt | May 2010 | A1 |
Number | Date | Country |
---|---|---|
0637431 | Feb 1995 | EP |
1459691 | Sep 2004 | EP |
WO-03082363 | Oct 2003 | WO |
WO-2005112791 | Dec 2005 | WO |
WO-2006017023 | Feb 2006 | WO |
WO-2006124896 | Nov 2006 | WO |
WO 2008042034 | Apr 2008 | WO |
WO 2008070238 | Jun 2008 | WO |
WO 2008097955 | Aug 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20060271078 A1 | Nov 2006 | US |
Number | Date | Country | |
---|---|---|---|
60680388 | May 2005 | US |